quindoxin has been researched along with Colonic Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| El-Khatib, M; Gali-Muhtasib, H; Geara, F; Haddadin, MJ | 1 |
| Diab-Assaf, M; Gali-Muhtasib, HU; Haddadin, MJ | 1 |
| Assaad, C; Diab-Assef, M; Gali-Muhtasib, HU; Haddadin, MJ; Yared, P | 1 |
3 other study(ies) available for quindoxin and Colonic Neoplasms
| Article | Year |
|---|---|
Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21.
Topics: Antineoplastic Agents; Carcinoma; Cell Death; Cell Hypoxia; Cell Proliferation; Cells, Cultured; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Evaluation, Preclinical; HCT116 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Oxygen; Quinoxalines; Tumor Suppressor Protein p53 | 2010 |
Quinoxaline 1,4-dioxides induce G2/M cell cycle arrest and apoptosis in human colon cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Division; Cells, Cultured; Colonic Neoplasms; Cyclin B; Extracellular Signal-Regulated MAP Kinases; Humans; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Quinoxaline 1,4-dioxides: hypoxia-selective therapeutic agents.
Topics: Aerobiosis; Antineoplastic Agents; Cell Hypoxia; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Humans; Kinetics; Quinoxalines; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |